Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases. Our pipeline is derived from our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications.
Mereo and Evgen's drugs both stumbled as phase 2 trials yielded disappointing results, but an AstraZeneca-style turnaround could be around the corner
